| Mary Gallager Kuras, CCC-SLP | |
|
2505 Ardmore St Se, Grand Rapids, MI 49506-4924 | |
| (616) 559-1054 | |
| (616) 559-1056 |
| Full Name | Mary Gallager Kuras |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 2505 Ardmore St Se, Grand Rapids, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033453386 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mary Gallager Kuras, CCC-SLP 2505 Ardmore St Se, Grand Rapids, MI 49506-4924 Ph: (616) 559-1054 | Mary Gallager Kuras, CCC-SLP 2505 Ardmore St Se, Grand Rapids, MI 49506-4924 Ph: (616) 559-1054 |
News Archive
The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.
The number of serious adverse drug events reported to the U.S. Food and Drug Administration (FDA) more than doubled between 1998 and 2005, as did deaths associated with adverse drug events, according to a report in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Oxygen Biotherapeutics, Inc., a development stage biomedical company focused on developing oxygen-rich intravenous and topical products, today announced that Israeli soldiers who suffer severe traumatic brain injury (TBI) can be enrolled in the company's Phase II-b STOP-TBI trials at clinical sites in Israel.
University of Manchester researchers funded by Breast Cancer Now have discovered a new explanation as to why women with oestrogen receptor positive (ER+) breast cancer develop resistance to hormone treatment, and a potential new approach to overcome the problem.
Researchers at the University of Exeter and UCL (University College London) have identified a gene which can be used to predict how susceptible a young person is to the mind-altering effects of smoking cannabis. The finding could help identify otherwise healthy users who are most at risk of developing psychosis.
› Verified 5 days ago
Katherine Devries, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1310 E. Beltline Ave Se, Suite 230, Grand Rapids, MI 49506 Phone: 616-288-3732 Fax: 616-288-9857 | |
Felicia Rose Bross, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3361 36th St Se, Grand Rapids, MI 49512 Phone: 616-942-2522 Fax: 616-956-3260 | |
Tommi Ann Wilde, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2900 Charlevoix Dr Se, Suite 200, Grand Rapids, MI 49546 Phone: 800-684-8049 | |
Julie Love, M.A, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2505 Ardmore St Se, Grand Rapids, MI 49506 Phone: 616-559-1054 | |
Amy Mcintosh, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 235 Wealthy St Se, Grand Rapids, MI 49503 Phone: 616-840-8000 | |
Scott Hower, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 360 Lafayette Ave Se, Suite 400, Grand Rapids, MI 49503 Phone: 616-486-6870 Fax: 616-454-6898 | |
Jill Margret Bradway, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1095 Medical Park Dr Se, Grand Rapids, MI 49546 Phone: 616-588-9210 |